{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 424750865
| IUPAC_name = 1-[3-(4-bromo-2-methyl-2''H''-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea
| image = Nelotanserin_structure.png
| width = 250px

<!--Clinical data-->
| tradename = 
| pregnancy_category = 
| legal_status = 
| routes_of_administration = [[Oral administration|Oral]]

<!--Pharmacokinetic data-->
| bioavailability = 
| metabolism = 
| elimination_half-life = 
| excretion = 

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 839713-36-9
| ATC_prefix = none
| ATC_suffix = 
| PubChem = 11683556
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 9858284
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 4ZA73QEW2P
| KEGG = D09645
| synonyms = APD-125

<!--Chemical data-->
| C = 18 | H = 15 | Br = 1 | F = 2 | N = 4 | O = 2
| molecular_weight = 437.238 g/mol
| SMILES = Brc1cnn(C)c1-c2cc(ccc2OC)NC(=O)Nc3ccc(F)cc3F
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C18H15BrF2N4O2/c1-25-17(13(19)9-22-25)12-8-11(4-6-16(12)27-2)23-18(26)24-15-5-3-10(20)7-14(15)21/h3-9H,1-2H3,(H2,23,24,26)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = COSPVUFTLGQDQL-UHFFFAOYSA-N
}}

'''Nelotanserin''' (former developmental code name '''APD-125''') is a [[drug]] developed by [[Arena Pharmaceuticals]] which acts as an [[inverse agonist]] on the [[serotonin receptor]] subtype [[5-HT2A receptor|5-HT<sub>2A</sub>]] and was under development for the treatment of [[insomnia]].<ref>{{Cite journal | last1 = Teegarden | first1 = B. R. | last2 = Li | first2 = H. | last3 = Jayakumar | first3 = H. | last4 = Strah-Pleynet | first4 = S. | last5 = Dosa | first5 = P. I. | last6 = Selaya | first6 = S. D. | last7 = Kato | first7 = N. | last8 = Elwell | first8 = K. H. | last9 = Davidson | first9 = J. | last10 = Cheng | doi = 10.1021/jm9007328 | first10 = K. | last11 = Saldana | first11 = H. | last12 = Frazer | first12 = J. M. | last13 = Whelan | first13 = K. | last14 = Foster | first14 = J. | last15 = Espitia | first15 = S. | last16 = Webb | first16 = R. R. | last17 = Beeley | first17 = N. R. A. | last18 = Thomsen | first18 = W. | last19 = Morairty | first19 = S. R. | last20 = Kilduff | first20 = T. S. | last21 = Al-Shamma | first21 = H. A. | title = Discovery of 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (Nelotanserin) and Related 5-Hydroxytryptamine2AInverse Agonists for the Treatment of Insomnia | journal = Journal of Medicinal Chemistry | volume = 53 | issue = 5 | pages = 1923–1936 | year = 2010 | pmid =  20143782| pmc = }}</ref> It was shown to be effective and well-tolerated in clinical trials,<ref>{{cite journal| last1= Rosenberg| first1= R| last2= Seiden| first2= DJ| last3= Hull| first3= SG| last4= Erman| first4= M| last5= Schwartz| first5= H| last6= Anderson| first6= C| last7= Prosser| first7= W| last8= Shanahan| first8= W| last9= Sanchez| first9= M| last10= Chuang| first10= E| last11= Roth| first11= T| title= APD125, a selective serotonin 5-HT<sub>2A</sub> receptor inverse agonist, significantly improves sleep maintenance in primary insomnia | journal = Sleep| volume= 31| issue= 12 | pages = 1663–71| year= 2008 | pmid= 19090322| pmc= 2603489 | display-authors= 8}}</ref><ref>{{Cite journal | last1 = Al-Shamma | first1 = H. A. | last2 = Anderson | first2 = C. | last3 = Chuang | first3 = E. | last4 = Luthringer | first4 = R. | last5 = Grottick | first5 = A. J. | last6 = Hauser | first6 = E. | last7 = Morgan | first7 = M. | last8 = Shanahan | first8 = W. | last9 = Teegarden | first9 = B. R. | last10 = Thomsen | doi = 10.1124/jpet.109.160994 | first10 = W. J. | last11 = Behan | first11 = D. | title = Nelotanserin, a Novel Selective Human 5-Hydroxytryptamine2A Inverse Agonist for the Treatment of Insomnia | journal = Journal of Pharmacology and Experimental Therapeutics | volume = 332 | issue = 1 | pages = 281–290 | year = 2009 | pmid =  19841476| pmc = }}</ref> but development was halted in December 2008 because the substance did not meet the trial's effectiveness endpoints.<ref>[http://www.arenapharm.com/wt/page/apd125.html APD125 for Insomnia]</ref>{{Dead link|date=August 2017}} Research continues on newer analogues which may potentially be more successful.<ref>{{Cite journal | last1 = Xiong | first1 = Y. | last2 = Ullman | first2 = B. | last3 = Choi | first3 = J. S. K. | last4 = Cherrier | first4 = M. | last5 = Strah-Pleynet | first5 = S. | last6 = Decaire | first6 = M. | last7 = Dosa | first7 = P. I. | last8 = Feichtinger | first8 = K. | last9 = Teegarden | first9 = B. R. | last10 = Frazer | doi = 10.1021/jm100479q | first10 = J. M. | last11 = Yoon | first11 = W. H. | last12 = Shan | first12 = Y. | last13 = Whelan | first13 = K. | last14 = Hauser | first14 = E. K. | last15 = Grottick | first15 = A. J. | last16 = Semple | first16 = G. | last17 = Al-Shamma | first17 = H. | title = Synthesis and in Vivo Evaluation of Phenethylpiperazine Amides: Selective 5-Hydroxytryptamine2A Receptor Antagonists for the Treatment of Insomnia | journal = Journal of Medicinal Chemistry | volume = 53 | issue = 15 | pages = 5696–5706 | year = 2010 | pmid =  20684606| pmc = }}</ref> More recently, nelotanserin has been repurposed for the treatment of [[Lewy body disease]].<ref name="AdisInsight">http://adisinsight.springer.com/drugs/800021795</ref> As of 2017, it is in [[Phases of clinical research#Phase II|phase II]] [[clinical trial]]s for this indication.<ref name="AdisInsight" />

==References==
{{Reflist|2}}

==External links==
* [http://adisinsight.springer.com/drugs/800021795 Nelotanserin - AdisInsight]

{{Serotonin receptor modulators}}

[[Category:5-HT2A antagonists]]
[[Category:Fluoroarenes]]
[[Category:Organobromides]]
[[Category:Phenol ethers]]
[[Category:Ureas]]

{{nervous-system-drug-stub}}